AstraZeneca breast cancer medicine slows disease by over six months
Tired of too many ads?
Remove Ads
New York: AstraZeneca Plc's experimental breast cancer pill delayed disease progression by over six months, according to data from a new study that is likely to capture investors' attention. Camizestrant , in combination with other cancer medicines, helped patients with a specific type of breast cancer to live for a median of 16 months without their cancer progressing, compared with 9.2 months for those taking the current standard treatment.Astra hopes the study data, presented at the American Society of Clinical Oncology's annual meeting in Chicago, will help establish a new treatment strategy for some breast cancer patients.Camizestrant works as a hormone therapy to stop estrogen from attaching to cancer cells and helping them to grow.When other potential uses for camizestrant are taken into account, Astra believes the drug could bring in over $5 billion in annual sales. But analysts are more cautious as other similar drugs have failed, with Barclays estimating potential peak year sales at $3.6 billion. AstraZeneca has established itself as a cancer drug powerhouse under CEO Pascal Soriot, with medicines including Tagrisso and Imfinzi fueling growth.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
20 hours ago
- Time of India
AI-based screening detects five cancer cases in early stages
Low dose Chest CT scan for individuals with a significant history of exposure to tobacco between the ages of 55 to 74, has been validated as a screening tool for early diagnosis of lung cancer. Panaji: The AI-driven early detection of lung cancer screening has been carried out across all levels of the public health system for free in Goa since Feb 2024. Over 75,000 chest X-rays have been screened, detecting over 6,000 pulmonary nodules and flagging more than 500 people with high risk for lung cancer. It also detected five lung cancer cases that would have otherwise gone undetected. Under the public-private partnership, Goa, in partnership with AstraZeneca and is the first state in the country to deploy artificial intelligence for lung cancer screening in the public sector. This was presented at the 78th World Health Assembly in Geneva in May by the state nodal officer for non-communicable disease cell, Dr Kedar Raikar. The screening currently takes place at 17 public health centres and hospitals. It is integrated with the existing digital X-ray network and conducts chest X-rays, CT scans, and follow-ups. The programme has reduced the wait time for CT scan from 10 days to 2 days for high-risk patients. The system helps flag potential signs on routine X-rays even when patients come in for completely unrelated issues. Before the system was brought in, 100 to 200 lung cancer cases would be detected over a two-year period. A pink slip is given to high-risk patients to ensure they receive prioritised care quickly. Stay updated with the latest local news from your city on Times of India (TOI). Check upcoming bank holidays , public holidays , and current gold rates and silver prices in your area.
India Today
06-08-2025
- India Today
Trump plans to initially impose ‘small tariffs' on pharma imports to boost US production
US President Donald Trump said on Tuesday that the United States would initially place a "small tariff" on pharmaceutical imports before hiking it to 150 per cent within 18 months and eventually to 250 per cent in an effort to boost domestic production."In one year, one and a half years maximum, it's going to go to 150% and then it's going to go to 250 per cent because we want pharmaceuticals made in our country," Trump told CNBC in an did not specify the initial tariff rate on pharmaceuticals. Trump said last month that pharmaceutical tariffs could reach as high as 200 per cent. He said in February that sectoral tariffs on pharmaceuticals and semiconductor chips would start at "25 per cent or higher," rising substantially over the course of a year. Trump said on Tuesday that he plans to announce tariffs on semiconductors and chips in the "next week or so," but gave no further United States has been conducting a national security review of the pharmaceutical sector, and the industry has been preparing for possible sector-specific tariffs. The administration has not announced when the results of that probe will be drugmakers have pledged multibillion-dollar investments in US manufacturing as Trump threatens import tariffs, with AstraZeneca recently committing USD 50 billion to expand its American the main lobbying group for the industry, did not immediately respond to a request for comment.A framework agreement between the United States and the EU sets out that tariffs on pharmaceuticals and semiconductors are currently zero, but if the United States raises tariffs following its import investigation, they will be capped at 15 per cent .- EndsTune InMust Watch
Indian Express
05-08-2025
- Indian Express
US to initially impose ‘small tariff' on pharma imports, Trump says
President Donald Trump said on Tuesday that the United States would initially place a 'small tariff' on pharmaceutical imports before hiking it to 150% within 18 months and eventually to 250% in an effort to boost domestic production. 'In one year, one and a half years maximum, it's going to go to 150% and then it's going to go to 250% because we want pharmaceuticals made in our country,' Trump told CNBC in an interview. He did not specify the initial tariff rate on pharmaceuticals. Trump said last month that pharmaceutical tariffs could reach as high as 200%. He said in February that sectoral tariffs on pharmaceuticals and semiconductor chips would start at '25% or higher,' rising substantially over the course of a year. Trump said on Tuesday that he plans to announce tariffs on semiconductors and chips in the 'next week or so,' but gave no further details. The United States has been conducting a national security review of the pharmaceutical sector, and the industry has been preparing for possible sector-specific tariffs. The administration has not announced when the results of that probe will be released. Several drugmakers have pledged multibillion-dollar investments in U.S. manufacturing as Trump threatens import tariffs, with AstraZeneca recently committing $50 billion to expand its American operations. PhRMA, the main lobbying group for the industry, did not immediately respond to a request for comment. A framework agreement between the United States and the EU sets out that tariffs on pharmaceuticals and semiconductors are currently zero, but if the United States raises tariffs following its import investigation, they will be capped at 15%.
